Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
AKBA's Cash to Debt is ranked higher than
72% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. AKBA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AKBA' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 12424.6
Current: No Debt
N/A
12424.6
Interest Coverage No Debt
AKBA's Interest Coverage is ranked higher than
62% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AKBA' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -55.06
AKBA's ROE (%) is ranked lower than
64% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. AKBA: -55.06 )
Ranked among companies with meaningful ROE (%) only.
AKBA' s ROE (%) Range Over the Past 10 Years
Min: -51.66  Med: -51.66 Max: -51.66
Current: -55.06
ROA (%) -48.41
AKBA's ROA (%) is ranked lower than
68% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. AKBA: -48.41 )
Ranked among companies with meaningful ROA (%) only.
AKBA' s ROA (%) Range Over the Past 10 Years
Min: -365.24  Med: -61.10 Max: -47.82
Current: -48.41
-365.24
-47.82
ROC (Joel Greenblatt) (%) -15645.51
AKBA's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. AKBA: -15645.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AKBA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -106220  Med: -31616.67 Max: -16403.47
Current: -15645.51
-106220
-16403.47
» AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AKBA Guru Trades in Q2 2015

Jim Simons 381,239 sh (New)
» More
Q3 2015

AKBA Guru Trades in Q3 2015

Jim Simons 110,700 sh (-70.96%)
» More
Q4 2015

AKBA Guru Trades in Q4 2015

Steven Cohen 42,000 sh (New)
Jim Simons 109,200 sh (-1.36%)
» More
Q1 2016

AKBA Guru Trades in Q1 2016

Paul Tudor Jones 18,498 sh (New)
Jim Simons 28,500 sh (-73.90%)
Steven Cohen 100 sh (-99.76%)
» More
» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:VNLPY, NAS:VSAR, NAS:ASND, OTCPK:MEOBF, NAS:CGEN, NAS:NLNK, NAS:TGTX, NAS:ARWR, NAS:SVA, OTCPK:ELVAF, NAS:VTAE, OTCPK:SPHDF, NAS:TRVN, NAS:NERV, NAS:LJPC, OTCPK:NICXF, NAS:CRVS, NAS:ARDX, NAS:BSTC, NAS:OMED » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.

Ratios

vs
industry
vs
history
P/B 2.01
AKBA's P/B is ranked higher than
72% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. AKBA: 2.01 )
Ranked among companies with meaningful P/B only.
AKBA' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 9.5
Current: 2.01
0
9.5
EV-to-EBIT -1.56
AKBA's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. AKBA: -1.56 )
Ranked among companies with meaningful EV-to-EBIT only.
AKBA' s EV-to-EBIT Range Over the Past 10 Years
Min: -4  Med: 0.00 Max: 0
Current: -1.56
-4
0
EV-to-EBITDA -1.56
AKBA's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. AKBA: -1.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4  Med: 0.00 Max: 0
Current: -1.56
-4
0
Current Ratio 16.37
AKBA's Current Ratio is ranked higher than
87% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. AKBA: 16.37 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 8.57  Med: 16.21 Max: 26.43
Current: 16.37
8.57
26.43
Quick Ratio 16.37
AKBA's Quick Ratio is ranked higher than
87% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. AKBA: 16.37 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 8.57  Med: 16.21 Max: 26.43
Current: 16.37
8.57
26.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.08
AKBA's Price/Net Cash is ranked higher than
85% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. AKBA: 2.08 )
Ranked among companies with meaningful Price/Net Cash only.
AKBA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 2.49 Max: 4.71
Current: 2.08
2.02
4.71
Price/Net Current Asset Value 2.05
AKBA's Price/Net Current Asset Value is ranked higher than
83% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. AKBA: 2.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AKBA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.99  Med: 2.43 Max: 4.65
Current: 2.05
1.99
4.65
Price/Tangible Book 2.02
AKBA's Price/Tangible Book is ranked higher than
77% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. AKBA: 2.02 )
Ranked among companies with meaningful Price/Tangible Book only.
AKBA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.98  Med: 2.40 Max: 4.63
Current: 2.02
1.98
4.63
Earnings Yield (Greenblatt) (%) -62.29
AKBA's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. AKBA: -62.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKBA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -132.22  Med: 0.00 Max: 0
Current: -62.29
-132.22
0

More Statistics

EPS (TTM) $ -2.43
Short Percentage of Float7.22%
52-Week Range $5.91 - 14.20
Shares Outstanding (Mil)37.98

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 16 53 69
EPS ($) -3.09 -3.27 -3.07
EPS w/o NRI ($) -3.09 -3.27 -3.07
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 28 2016
Akebia to Present at the Cantor Fitzgerald Annual Healthcare Conference Jul 05 2016
Akebia to Present at the Cantor Fitzgerald Annual Healthcare Conference Jul 05 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 21 2016
Akebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 Jun 02 2016
Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug... May 23 2016
Akebia to Present at the 2016 UBS Global Healthcare Conference May 16 2016
Akebia to Present at the 2016 UBS Global Healthcare Conference May 16 2016
AKEBIA THERAPEUTICS, INC. Financials May 13 2016
Akebia Therapeutics reports 1Q loss May 05 2016
Akebia Therapeutics reports 1Q loss May 05 2016
Akebia Announces First Quarter 2016 Financial Results and Provides Corporate Update May 05 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 05 2016
Akebia Announces First Quarter 2016 Financial Results and Provides Corporate Update May 05 2016
Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National... Apr 26 2016
Increased Earnings Estimates Seen for Akebia Therapeutics (AKBA): Can It Move Higher? Apr 13 2016
Akebia Therapeutics (AKBA): Strong Industry, Solid Earnings Estimate Revisions Apr 05 2016
Akebia to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
Akebia to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
Akebia Therapeutics (AKBA) Stock Down on Q4 Results Mar 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)